First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization
Center for Reproductive Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. Fertility and Sterility
(Impact Factor: 4.59).
04/2003; 79(3):621-3. DOI: 10.1016/S0015-0282(02)04804-5
To report the first pregnancy and live birth after ovarian stimulation using a chimeric long-acting human recombinant FSH agonist (recFSH-CTP) for IVF.
Tertiary fertility center.
A 32-year-old woman with a 7-year history of primary infertility.
Ovarian stimulation with a single SC injection of 180 microg recFSH-CTP on cycle day 3, followed by daily injections of 150 IU recFSH from cycle day 10 onward, combined with daily GnRH antagonist 0.25 mg SC to prevent a premature LH rise. Final oocyte maturation was induced by 10,000 IU hCG.
First ongoing pregnancy obtained with recFSH-CTP.
Twelve oocytes were retrieved. Ten oocytes were fertilized in vitro by intracytoplasmic sperm injection, and from these 10 oocytes, two embryos were subsequently transferred after 3 days of culture. A pregnancy test 2 weeks after ET was positive, and ultrasound investigation revealed an intact, intrauterine, singleton pregnancy after 12 weeks.
The first pregnancy and live birth was achieved after ovarian stimulation using recFSH-CTP for IVF.
Available from: PubMed Central
- "In 2003, Tae-Ki Yoon and his working group reported a live birth after vitrification in a stimulated IVF-ET program (94). The first IVF birth after ovarian stimulation by a long-acting human recombinant follicle stimulating hormone (rFSH) agonist was reported (95). Dr. Barash and Prof. Dekel demonstrated increased IVF implantation rate following endometrial curettage by Pipelle curette as a simple outpatient procedure (96). "
[Show abstract] [Hide abstract]
ABSTRACT: Public interest in Assisted Reproductive Technology (ART) has remained high since the birth of the world's first in vitro fertilization baby, Louise Brown, in the United Kingdom. ART allows scientists to manipulate the fertilization process in order to bypass some pathological obstacles such as blocked fallopian tubes and non-functioning ovaries in the females, and blocked vas deferens and low sperm count in the males. The purpose was to provide a historical outline and identify the researches that most contributed to ART.
A review of published experimental and clinical studies of assisted reproduction carried out at the University of Bristol library website (MetaLib(®)). A cross-search of seven different medical databases (AMED-Allied and Complementary Medicine Database, BIOSIS Previews on Web of Knowledge, Cochrane Library, Embase, and the Medline on Web of Knowledge, OvidSP and PubMed) was completed by using the key words to explore the major milestones and progress in the development and implementation of ART.
A speedy advancement in the development of different assisted reproductive techniques makes infertility problem more treatable than it ever had been.
Although no other field in the medicine has integrated new knowledge into the daily practice more quickly than ART yet, there is a need for social research to counterbalance the dominance of biomedical one, in particular the people's actual experiences and expectations of ART.
Journal of Reproduction and Infertility 03/2013; 14(3):96-109. DOI:10.4172/2161-0932.1000156
Available from: Bruno Lunenfeld
- "A study in healthy female volunteers showed that a single dose of rFSH-CTP induced multiple follicular growth accompanied by a dose-dependent rise in serum inhibin-B (Duijkers et al., 2002). The first live birth after ovarian stimulation using a chimeric long-acting human rFSH agonist (rFSH-CTP) was reported by Beckers et al. (2003). Ovarian stimulation was initiated on day 3 of a spontaneous menstrual cycle with 180 mg rFSH-CTP. "
[Show abstract] [Hide abstract]
ABSTRACT: The 20th century witnessed the steady development of knowledge about the reproductive process in animals and humans. These advances led to the identification of higher centres governing the dynamics of ovarian function and to the discovery of gonadotrophic hormones. As the mechanisms of action of these hormones became increasingly understood, they began to be used in the management of infertility during the early 1930s. Hormone extracts were originally prepared from animal pituitaries and pregnant mare serum, as well as from human pituitaries, placenta and urine, with pregnancies reported following their use in the late 1930s. This review traces the constant quest to reduce risks and improve safety and efficacy of hormone preparations for patients. It describes the complex path and perils leading to the pure hormone preparations that are available today, concluding with an optimistic glimpse towards the future. Small molecules that are orally active and specific are currently being investigated, some with the capacity to bypass many parts of the receptor conformation. Here lies the immediate future of this field, utilizing low-cost, small, defined molecules to stimulate follicle growth, ovulation and corpus luteum formation. Perhaps one day the classical gonadotrophins will no longer be required in clinical treatment.
Human Reproduction Update 09/2004; 10(6):453-67. DOI:10.1093/humupd/dmh044 · 10.17 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Ovulation induction has developed as a valuable noninvasive therapy for the infertile couple. The nurse's role focuses on assisting the couple, as a unit, to understand and cope with the necessary regimen, tests, examinations, and therapies necessary to reach the goal of conception. The physiologic regulation of the menstrual cycle, current pharmacologic therapy, treatment protocols, and the unique role of the infertility nurse are reviewed.
Journal of Obstetric Gynecologic & Neonatal Nursing 11/1985; 14(s6). DOI:10.1111/j.1552-6909.1985.tb02798.x · 1.02 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.